Colipral®

Colipral® is a next-generation probiotic supplement based on Escherichia coli 5C (ECP24®), a highly characterized strain of human origin representing a breakthrough in precision microbiome modulation. Combining genetic stability, certified safety and high functional activity, Colipral® introduces a new paradigm in E. coli-based probiotics for clinical use. The strain demonstrates a strong ability to adhere to intestinal cells and compete with pathogenic E. coli at the receptor level, supporting microbiota balance and contributing to the prevention of recurrent urogenital infections. At the same time, its metabolic activity promotes acetate production, fostering butyrate synthesis through cross-feeding mechanisms, and supporting intestinal homeostasis. Colipral® also exhibits anti-inflammatory and immunomodulatory activity, including increased IL-10 production, and has been investigated in conditions such as ulcerative colitis in remission and post-colonoscopy microbiota recovery. Thanks to its gastroprotected formulation, the strain reaches the intestine intact, ensuring targeted delivery and optimal efficacy. With its precision-driven mechanism and strong scientific characterization, Colipral® stands out as an innovative solution in the evolving microbiome space.